Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
Latest Information Update: 19 Mar 2024
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms PULSOV
- 13 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2024 Planned End Date changed from 1 May 2024 to 23 Mar 2025.
- 15 Feb 2024 Planned primary completion date changed from 1 May 2024 to 23 Mar 2025.